- Home
- VCYT vs KNSA Comparison
VCYT vs KNSA Comparison
Compare VCYT & KNSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VCYT
- KNSA
- Stock Information
- Founded
- VCYT 2006
- KNSA 2015
- Country
- VCYT United States
- KNSA United Kingdom
- Employees
- VCYT N/A
- KNSA N/A
- Industry
- VCYT Medical Specialities
- KNSA Biotechnology: Pharmaceutical Preparations
- Sector
- VCYT Health Care
- KNSA Health Care
- Exchange
- VCYT Nasdaq
- KNSA Nasdaq
- Market Cap
- VCYT 2.4B
- KNSA 2.6B
- IPO Year
- VCYT 2013
- KNSA 2018
- Fundamental
- Price
- VCYT $31.83
- KNSA $35.43
- Analyst Decision
- VCYT Buy
- KNSA Strong Buy
- Analyst Count
- VCYT 9
- KNSA 6
- Target Price
- VCYT $39.89
- KNSA $40.83
- AVG Volume (30 Days)
- VCYT 921.3K
- KNSA 402.6K
- Earning Date
- VCYT 11-05-2025
- KNSA 10-28-2025
- Dividend Yield
- VCYT N/A
- KNSA N/A
- EPS Growth
- VCYT N/A
- KNSA N/A
- EPS
- VCYT 0.34
- KNSA 0.07
- Revenue
- VCYT $479,129,000.00
- KNSA $529,332,000.00
- Revenue This Year
- VCYT $14.19
- KNSA $37.21
- Revenue Next Year
- VCYT $9.68
- KNSA $11.99
- P/E Ratio
- VCYT $95.21
- KNSA $538.95
- Revenue Growth
- VCYT 19.91
- KNSA 56.18
- 52 Week Low
- VCYT $22.61
- KNSA $17.82
- 52 Week High
- VCYT $47.32
- KNSA $37.34
- Technical
- Relative Strength Index (RSI)
- VCYT 58.59
- KNSA 57.08
- Support Level
- VCYT $30.67
- KNSA $35.72
- Resistance Level
- VCYT $32.34
- KNSA $37.34
- Average True Range (ATR)
- VCYT 1.18
- KNSA 1.01
- MACD
- VCYT -0.06
- KNSA -0.12
- Stochastic Oscillator
- VCYT 73.71
- KNSA 53.31
About VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run in CLIA labs in support of clinical studies.
About KNSA Kiniksa Pharmaceuticals Ltd.
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.